Filtered By:
Source: Cancer Research
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 807 results found since Jan 2013.
Abstract 1656: MK-1775 (WEE1 inhibition) lacks efficacy against DNA repair deficient pancreatic cancer cells
Conclusions: These results support a paradigm in which identified high risk FA/BRCA2-mutated patients would not benefit from WEE1 inhibitor monotherapy; and thus, would most likely respond better to conventional DNA damaging agent-based therapies (e.g., oxaliplatin or MMC).Citation Format: Shruti Lal, Saswati N. Chand, Emanuela Dylgjeri, Charles J. Yeo, Jordan M. Winter, Jonathan R. Brody. MK-1775 (WEE1 inhibition) lacks efficacy against DNA repair deficient pancreatic cancer cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Phi...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Lal, S., Chand, S. N., Dylgjeri, E., Yeo, C. J., Winter, J. M., Brody, J. R. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1663: Selective CDK8 inhibitor SEL120-34A alters expression of interferon-related DNA damage resistance signature genes in colorectal cancer
CDK8 (cyclin-dependent kinase 8) is a kinase component of a multi - protein Mediator complex, involved in transcription control. Several studies indicated that high overexpression and activity of CDK8 could be a driver of malignant progression in colorectal cancer (CRC). Herewith we present molecular insights into mechanism of action of SEL120-34A - a selective small molecule inhibitor of CDK8 kinase. Biochemical and binding studies indicated that SEL120-34A selectively binds and inhibits enzymatic activity of CDK8 in the low nM range. Recently CDK8 has been described as a regulator of STAT1 activity in NK cells where by p...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Rzymski, T., Mikula, M., Szaȷewska–Skuta, M., Zyłkiewicz, E., Sapała, Łukasz, Dolata, I., Kitliłska, A., Goryca, K., Grochowska, A., Cabaȷ, A., Dreas, A., Kucwaȷ, K., Białas, A., Radzimier Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1919: Warfarin-dependent gamma-carboxylation regulates androgen receptor activity
The anti-coagulant warfarin prevents the gamma-carboxylation (gla) of target proteins by interfering with the vitamin K cycle through its inhibition of the vitamin K epoxide reductase (VKOR). Most known gla proteins are found in the blood clotting cascade, but we demonstrate using immunoprecipitation and mass spectrometry that the androgen receptor (AR) can also be gamma-carboxylated. This modification occurs at amino acid 2E and can be prevented by warfarin treatment. This residue has been found to be mutated in partial androgen insensitivity syndrome patients. Warfarin, likely through its ability to control carboxylation...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Tew, B. Y., Hong, T., Pal, S. K., Kalkum, M., Jones, J. Tags: Prevention Research Source Type: research
Abstract 1671: Fibroblast growth factor receptor 3 enhances progression of hepatocellular carcinoma
Conclusions: Upregulated FGFR3 is associated with development and progression of hepatocellular carcinoma. Accordingly, blockade of FGFR3-mediated signaling may be a promising therapeutic approach to antagonize growth and malignant behavior of HCC cells.Citation Format: Jakob Paur, Lisa Nika, Christiane Maier, Julia Kostka, Petra Heffeter, Sonja Kappel, Daniela Kandioler, Klaus Holzmann, Brigitte Marian, Walter Berger, Michael Grusch, Bettina Grasl-Kraupp. Fibroblast growth factor receptor 3 enhances progression of hepatocellular carcinoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Paur, J., Nika, L., Maier, C., Kostka, J., Heffeter, P., Kappel, S., Kandioler, D., Holzmann, K., Marian, B., Berger, W., Grusch, M., Grasl-Kraupp, B. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1434: MDM2 promotes tumor cell migration through the induction of epithelial to mesenchymal transition
Conclusion: In summary, this study explored the molecular mechanisms underlying the role of MDM2 in cancer progression. MDM2 expression has been demonstrated to be closely correlated to human ovarian adenocarcinoma clinical staging, indicating the possible utilization of MDM2 in prognosis. Further study clarified MDM2 promoted tumor cell migration through the induction of EMT, which provides new theoretical evidences for the roles that MDM2 plays in tumor metastasis. Our study implicates that MDM2 may be a potential target for inhibiting metastasis and contributes to the translational research of MDM2 inhibitors as anti-me...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Zheng, L., Wu, Y., Zhou, T., Zhu, H., He, Q., Yang, B. Tags: Tumor Biology Source Type: research
Abstract 1942: Regulation of GRNMB transcription and cellular effects by chondroitin 4-sulfation
Increased expression of glycoprotein (transmembrane) NMB (GPNMB; osteoactivin) has been identified in triple negative breast cancer, melanoma, glioma, and hepatocellular carcinoma, and followed decline in expression of the enzyme arylsulfatase B (ARSB; N-acetylgalactosamine 4-sulfatase). The expression and regulation of GPNMB was evaluated in HepG2 cells and in ARSB-deficient and control C57BL/6J mouse hepatic tissue. Increased expression of GPNMB was attributable to promoter activation by phospho(Ser)MITF (microphthalmia-associated transcription factor), the phosphorylation of which was activated by phospho(Ser)-p38 MAPK....
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Tobacman, J. K., Feferman, L., Bhattacharyya, S. Tags: Molecular and Cellular Biology Source Type: research
Abstract 1443: BMP-2 induces motility and invasiveness of colon cancer through upregulation of cancer stem cell
In this study, we investigated the function of BMP-2 and relevance BMP-2 and CSCs in Colon cancer cells.First, We compared the endogenous protein level of parental and spheroid cells by western blotting. The spheroid cells showed higher level of EMT(Epithelial mesenchymal transition) markers N-Cadherin and Snail, CSC markers (EpCAM and CD133), and p Smad1/5 known BMP-2 downstream than the corresponding parental cells. Then expression of EpCAM and CD133 was confirmed by flow cytometry. We found that BMP-2 plays a key role in Cancer stem cell. To determine function of BMP-2 in Colon cancer cells, we stimulated the colon canc...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kim, B. R., Kim, J. L., Park, S. H., Jeoung, Y. A., Lee, S. I., Min, B.-W., Oh, S. C. Tags: Tumor Biology Source Type: research
Abstract 1713: IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis
ConclusionsOur study results demonstrate that IL-24 inhibits lung tumor cell migration and invasion by disrupting the SDF-1/CXCR4 signaling pathway and exhibits enhanced anti-metastatic activity when combined with CXCR4 inhibitors.Citation Format: Janani Panneerselvam, Jiankang Jin, Manish Shanker, Jason Lauderdale, Jonathan Bates, Qi Wang, Daniel Zhao, Stephen Archibald, Timothy Hubin, Rajagopal Ramesh. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Panneerselvam, J., Jin, J., Shanker, M., Lauderdale, J., Bates, J., Wang, Q., Zhao, D., Archibald, S., Hubin, T., Ramesh, R. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1714: The role and mechanism of JAB1 as a therapeutic target in biliary tract cancer
Conclusion: Suppression of Jab1 shows antitumor effects in BTC cells by inhibiting cell proliferation, migration, cell cycle and increase of chemosensitivity. Taken together, Jab1 might be a potential therapeutic target in BTC.Citation Format: Ah-Rong Nam, Kyo Hwa Kang, Ji Eun Park, Ju-Hee Bang, Ling Jin, Mei Hua Jin, Tae Yong Kim, Sae-Won Han, Sang-Hyun Song, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang. The role and mechanism of JAB1 as a therapeutic target in biliary tract cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia,...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Nam, A.-R., Kang, K. H., Park, J. E., Bang, J.-H., Jin, L., Jin, M. H., Kim, T. Y., Han, S.-W., Song, S.-H., Im, S.-A., Kim, T.-Y., Oh, D.-Y., Bang, Y.-J. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1724: Integrated functional RNAi screening and structural genomics identify inverse co-modulators of TP53 family and NF-{kappa}B transitional activation as potential therapeutic targets in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide with a 50-60% mortality rate. Deregulation of p53 family members in HNSCC occurs in over 90% of cases, preventing transcription of growth arrest and apoptosis genes. Conversely, members of the NF-κB/REL family are aberrantly activated in about ∼70% of cases, and drive expression of pro-proliferation, inflammation, angiogenesis, and therapeutic resistance genes. The function of different TP53 and NF-κB family members are inversely modulated within two major subsets of HNSCC, suggesting that common molecules and pathways coordinate this...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Saleh, A., Cornelius, S., Martin, S., Ormanoglu, P., Cheng, H., Das, R., Yang, X., Chen, Z., Van Waes, C. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1726: CRM1 is overexpressed in lung tumorigenesis and represents an adjuvant target for lung cancer treatment
The objectives of the present study are to evaluate the involvement of CRM1 in lung carcinogenesis and lung cancer treatment. First, we have analyzed the importance of CRM1 overexpression in lung cancer development. We showed that CRM1 was overexpressed in lung tumor tissues from lung cancer patients and lung adenocarcinoma in mice induced by a tobacco carcinogen, as well as lung cancer cell lines. The increased CRM1 expression levels in these lung cancer tissues and cells were associated with an increased phosphorylation level at threonine residue 55 of the p53 protein. Furthermore, CRM1 overexpression in lung cancer cell...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Gao, W., Lu, C., Chen, L., Keohavong, P. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1735: Identification of novel synthetic lethal interactions in small cell lung cancer with the proteasome inhibitor carfilzomib
Proteasome inhibition (PI) has emerged as a valuable cancer treatment in hematological malignancies by causing a disruption of protein homeostasis. While proteasome inhibitors have been historically unsuccessful in the clinic for solid tumors, all cancer cell lines succumb to proteasome inhibition in vitro. Solid tumor cell lines have a higher threshold for disruption of protein homeostasis; as they require continuous exposure to achieve cytotoxicity similar to pulsatile exposure of PI in heme cell lines. The in-vivo half-life of proteasome inhibitors is short (∼1hr) making it challenging to mimic in vitro continuous tre...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Masto, V. B., Lerner, A. G., Arastu-Kapur, S. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1505: Suppression of triple-negative breast cancer tumorigenesis by targeting cancer stem cells through JNK/Notch1 signaling inhibition
Background: Triple-negative breast cancer (TNBC) is an aggressive disease with a poor prognosis and lacks targeted therapies. Basal-like TNBC exhibits hyperactivated JNK (c-Jun N-terminal kinase). JNK plays a vital role in malignant transformation of different cancers. However, it is unknown whether JNK signaling is a clinically relevant target in TNBC. Here, we tested the hypotheses that JNK signaling plays a fundamental role in TNBC pathogenesis by promoting self-renewal of cancer stem cells (CSCs).Methods: The role of JNK signaling in TNBC pathogenesis was determined by examining the effects of JNK signaling inhibition ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Xie, X., Kaoud, T. S., Edupunganti, R., Zhang, T., Kogawa, T., Chauhan, G. B., Giannoukos, D. N., Qi, Y., Tripathy, D., Gray, N. S., Dalby, K. N., Bartholomeusz, C., Ueno, N. T. Tags: Tumor Biology Source Type: research
Abstract 1785: Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner
The mechanisms that determine p53 cell fate decision after its non-genotoxic activation by MDM2 inhibitors are poorly understood. Wild-type p53-inducible phosphatase-1 (WIP1/PPM1D) forms an autoregulatory loop with p53 and is involved in the homeostasis of the p53 stress response network. WIP1 is activated, gained/amplified and overexpressed in a range of p53 wild-type malignancies.We investigated cellular growth/proliferation of p53 wild-type (wt) and matched p53 mutant (mut)/null cell line pairs, differing in WIP1 genetic status, in response to Nutlin-3 + GSK2830371 (WIP1i)/WIP1 siRNA-mediated knockdown. We also assessed...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Esfandiari, A., Curtin, N. J., Lunec, J. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1848: PPAR{gamma} function is attenuated by full length androgen receptor and the AR-V7 variant in human prostate cancer cells
The peroxisome proliferator activated receptor gamma (PPARγ) is a ligand-activated transcription factor that regulates in vitro and in vivo growth of castration-resistant human prostate cancer (PCa) cells. However, the factors that control expression of PPARγ within human PCa have not been characterized. We have previously shown that the androgen dihydrotestosterone decreases PPARγ levels and transcriptional activity in human PCa cells. Dihydrotestosterone serves as a high affinity ligand for the 110 kD form of the androgen receptor (AR-FL). Recent studies have shown the development of castration-resistant forms of pros...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Olokpa, E., Stewart, L. V. Tags: Endocrinology Source Type: research
